Daniel C. Adelman M.D. is Chief Medical Officer at Aimmune Therapeutics, Inc. (AIMT). They have made 7 open-market trades across 1 company since 2017, most recently 2020-10-13.
CIK 0001222037
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 7 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| AIMT | 63,807 | $2.2M |
Shares reported on the most recent Form 4, priced at the 2020-10-05 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| AIMT | SELL | 2020-01-02 | 2020-01-03 | $35.00 | $700K | +1.4% | -5.4% | -60.0% |
| AIMT | SELL | 2019-12-09 | 2019-12-11 | $30.04 | $601K | +3.9% | +1.2% | -37.3% |
| AIMT | SELL | 2018-01-12 | 2018-01-16 | $40.00 | $1.5M | -3.1% | -0.2% | -19.0% |
| AIMT | SELL | 2017-12-27 | 2017-12-29 | $40.00 | $131K | +1.6% | -4.2% | -16.3% |
| AIMT | SELL | 2017-10-23 | 2017-10-25 | $33.82 | $575K | -1.3% | +15.1% | +22.0% |
| AIMT | SELL | 2017-10-23 | 2017-10-25 | $34.06 | $341K | -1.3% | +15.1% | +22.0% |
| AIMT | SELL | 2017-09-25 | 2017-09-27 | $25.00 | $250K | +0.2% | +17.5% | +53.8% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.